Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MM-302

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merrimack

Drug class:

Topoisomerase II inhibitor, HER2-targeted antibody-drug conjugate

Related drugs:

‹

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

ado-trastuzumab emtansine (97)

fam-trastuzumab deruxtecan-nxki (90)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MM-302 Sensitive: C2 – Inclusion Criteria MM-302 Sensitive : C2	MM-302 Sensitive: C2 – Inclusion Criteria MM-302 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + MM-302 Sensitive: C3 – Early Trials trastuzumab + MM-302 Sensitive : C3	trastuzumab + MM-302 Sensitive: C3 – Early Trials trastuzumab + MM-302 Sensitive : C3
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab + MM-302 Sensitive: D – Preclinical trastuzumab + MM-302 Sensitive : D	trastuzumab + MM-302 Sensitive: D – Preclinical trastuzumab + MM-302 Sensitive : D
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab + MM-302 Sensitive: D – Preclinical trastuzumab + MM-302 Sensitive : D	trastuzumab + MM-302 Sensitive: D – Preclinical trastuzumab + MM-302 Sensitive : D